Member Info for oogleflugal

News driven. Lack of news. Where are all these exciting new contracts?

Stand corrected SB. I assumed because of all the conventions she had spoken at she was from a medical diagnostic background. She seems to have a lot of experience in it. Tutivia is just one product which they are going to throw everything at at the expense of slowing down one and moth balling the other. They have terrific international potential as well as the Job in hand, America. All I can say is I think this company will be worth a lot and will be partaking in the placing given the chance.

NAV currently £2.30 pershare with negligible debt and liabilities . Is the business really only worth 27p per share? Cant see this lasting long before bids come in. Would be a real shame to see this go. I confess my family had small stakes in this as part of their portfolios which served them well. Always looked too pricey for me until the market unfathomably decided it was worth less than its asset value. That is the uk market , one of absurd extremes.

‘Do you believe them’ ? They have been in business for more than 120 years! Amazing they are still independent, though that may not be the case for much longer. They opened a brand new ‘ state of the art centre ‘ in Norfolk opened in 2021 despite the pandemic. They have new facilities in USA and France and are pushing to capitalise business in China. Not bad going for four years of reset. All that capex spend is now complete and they are just cash positive again. They have addressed new trends and dont sit on their laurels of past glories watching the world go by. I think it is normal for there to be a period of consolidation and management changes are also inevitable. Absolutely right its a question of whether shareholders believe them. If not somebody will take them out for another bargain price as another uk company gets stolen

Euston. Give it another 5 years! Gl

Verci. I think it has been proved all too often what lousy CEOs scientists make. However she seems to be surrounded by those who should perhaps know better. Perhaps they have been a little unfortunate in the delay with Medicare approval. Chris Mills didnt seem to think Vrci would require any more funding last year. He is the largest holder at 15%. ‘It will need to be a 100 bagger’ depends on several things. How much you paid for the stock in the first place and how they raise the cash, as there might be alternatives. It matters quite considerably as to whether the test becomes mandatory . I did lay out the figures of the addressable market. Some patients may end up having several tests. A bigger concern might be the availability of donors. They are currently only managing to service a third of demand. Presumably they would eventually like this tests to have global coverage. At the current time there is no competitive or alternative test that can detect rejection at a crucially early stage with the same accuracy. This is a massive advantage which can save wasting expensive, potentially toxic treatment being administered to the wrong patient. Save valuable time and surgery, improve patient outcome and most of all catch up on the severe backlog of kidney patients. The CEO has acknowledged most of this in the RNS and is clearly desperate to hit the turbo charge button ti supply the demand. Cant deny this hold up has been an expensive delay and completely derailed the revenue stream by nearly a year. They can now catch up on the revenue, but the bulk of the raise will to accelerate growth not debt.

Lord J lee has been invested here forever. He did an interview with IC yesterday . Everyone seems to be wondering how this ever got to over £12. Aside from the challenging trading conditions of the last 6 months, which they expect to be a temporary blip, they have also been going through a bit of reorganisation themselves . This comes as a bit of a reorganisation of the board of directors which often creates a period of uncertainty. The interim CEO Ryan Govender returned to his CFO position with added duties by the newly appointed CEO last June. Now CFO Ryan is off to a new company himself. These situations can cause a bit of friction. However after some capex spend and a new sample lab opening in France last month, some redirection in products such as steering towards less sugary products, they look reset for a new chapter. Its not going back to £12 but as the sage, Lord Lee remarked, it does appear to have gone from one ludicrous extreme to another, way over priced to way under value, leaving itself vulnerable to the hungry acquisitive mob.

Not bad money is potentially getting guaranteed million quid for raising 2 million. I like some of that Nige. Got a couple of mice in the attic for sale for 500000k each

Sch. Wouldnt we all! Turner Pope have written a glowing report based on the latest mouse test . So we are still at an early stage ten years and several million down the pan. TP have about 100,000,000 exercisable warrants for all the placings they have overseen. Then there the exercisable warrants for Nige and chums .

At the meeting the board made such a deal about not being able to buy shares at this price , I’m quite surprised they are not piling in yet. One thing that crossed my mind, which I think has been mentioned before, is a reverse spinout. They stated that as well as buybacks they would be interested in acquiring a suitable company. Perhaps Verci is not quite at the right stage of development, but a lot to be said for keeping in the family.

Barrington did say the test had become mandatory in one health centre and was achieving that kind of recognition in 4 others. They are in about 20 centres now. Hence her statement ‘growth is there we just have to go and grab it.’ Whether they need 5million or ten million to get through the next 12 months is mere drop in the ocean . I can well understand that with this kind of diagnostic available it would be negligent not to use it to get the best possible outcome for patients. They have an addressable market of 72 million dollars in the USA just for 1 test each It could be much more . That has to be worth a lot more than its current feeble market cap. Sure it remains to be seen how quickly they can scale up, how quickly it becomes universally accepted and I think Medicare expect to cover payment of at least 60 % of transplant cases. Surprised how liquid shares are. Can get electronic quotes to buy or sell sizeable positions.

28,000 kidney transplants in Us last year with 90,000 waiting. Over 100,000 kidney transplants world wide.

Yes the leaky ship strikes again but frankly we’ve heard it all before. The key word is ‘art early stage ‘ . Aren’t the always . Real need is a deal otherwise it’s just Trumpeting

‘Where complexity meets clarity’. Pity they can’t apply their own mantra to how they run their business. With more vagueness for another two weeks they should be suspended.

So we are going to have a fund raise which we knew but they haven’t yet determined how much because they don’t yet have the authority to do it! Struth!

Typo Amati not Artemis

Is that not the whole point of accurate diagnostics , get the right treatment to the right patient , save money and improve patient recovery

Thanks for your thoughts SB. Trading on this is just ridiculous now. There was A UT trade at 1.47p for about 30 quid. I bought 100,000 at 1.60p, didn’t move the dial a fraction. I can’t see Harwood and Co letting this go. they have 15 percent on their own. There have been no notifiable trades since Artemis in January and the one about Maven taking over recently . GL

Dont know where Lse get their prices from. Just rewatched the interview between Paul Hill and Sarah Barrington last month. 68% quarter growth . Tutivia tests on the way to being mandatory in several health centres. Outlook was a bit disappointing, as it is for most, but they should have better cash generation now. Until they get the invoicing going I cant see how they can be clear how much they need to raise to fund the growth ‘that is there for the taking.’ They are at that magical inflexion point. I’d be surprised if there is not a stampede of offerings for the raise, so no need to give away shares cheaply imo.

No idea how reliable any of the lists published about holdings are, none of them are the same.. On Verici’s own page it still has Artemis on 5.1% as of 31/03/25. The january rns states they had reduced to 5.38%. No mention of Maven in that list then either. They should be receiving some cash from invoicing on the now insurance validated tests dating back to last year.